Full-Time

Senior Manufacturing Operator

Updated on 8/24/2026

Kyowa Kirin

Kyowa Kirin

1,001-5,000 employees

Global specialty pharma focused on antibodies

Compensation Overview

$33 - $45/hr

+ Annual bonus + Long-term incentive program

Sanford, NC, USA

In Person

The role is 100% on-site and requires up to 10% domestic and international travel.

Bachelor's, Associate's

Category
Biology & Biotech (1)
Required Skills
Microsoft Office
Agile
ERP
Process Engineering

Get referred to Kyowa Kirin

See people who can refer or advise you

Requirements
  • A Bachelor's degree plus a minimum of 4 years of relevant biopharmaceutical manufacturing experience, or an Associate's degree plus a minimum of 6 years, or a High School Diploma/GED plus a minimum of 8 years.
  • Direct upstream and downstream Good Manufacturing Practice manufacturing experience.
  • Experience with upstream operations including vial thaw/inoculation, wave bioreactors, single-use bioreactors from 50L to 3000L, and harvest operations.
  • Experience with downstream operations including chromatography, viral inactivation, viral filtration, tangential flow filtration systems, and bulk filling.
  • Knowledge of Agile and Lean Manufacturing principles and Standard Work.
  • Proficiency with Microsoft Office applications.
  • Strong problem-solving and critical-thinking skills.
  • Ability to maintain clean manufacturing environments in accordance with Good Manufacturing Practice and safety standards.
  • Ability to read and interpret technical documents.
  • Ability to troubleshoot and operate production equipment.
  • Ability to perform basic math and statistics.
  • Strong written and verbal English communication skills.
  • Ability to lift up to 35 pounds and move heavy objects.
  • Ability to stand for three or more hours while operating equipment.
  • Ability to comply with gowning and personal protective equipment requirements.
Responsibilities
  • Execute manufacturing operations on the manufacturing floor for monoclonal antibody manufacturing, including weigh and dispense, bioreactors, filtration equipment, inoculum preparation, chromatography skids, and ultrafiltration/diafiltration skids through process control and manufacturing execution systems.
  • Perform processes according to safety and compliance policies, current Good Manufacturing Practices, applicable requirements, and ALCOA+ data integrity practices.
  • Follow operational procedures, master records, and written and verbal instructions from supervisors.
  • Maintain accurate batch records, log sheets, and other required documentation.
  • Escalate perceived or actual non-compliance events in a timely manner.
  • Collaborate with Process Engineering, Automation, Commissioning, Qualification and Validation, Quality, Operational Excellence, and Warehouse teams during commissioning and manufacturing operations.
  • Participate in Factory Acceptance Tests and facilitate equipment validation and qualification with Engineering teams.
  • Identify and implement process improvements to optimize operations.
  • Lead initiatives to streamline workflows and eliminate waste.
  • Use enterprise systems supporting manufacturing operations, including enterprise resource planning, laboratory information management systems, manufacturing execution systems, process control systems, quality management systems, and building management systems.
  • Lead floor-level troubleshooting and resolution of equipment, automation, and process issues, and support corrective and preventive action tracking and documentation.
  • Maintain cleanliness and organization of manufacturing areas through routine cleaning and preventive maintenance.
  • Manage shop-floor activities using 5S, Standard Work, and Kanban methodologies.
  • Coordinate with Warehouse and Maintenance teams to ensure uninterrupted availability of materials, supplies, and equipment.
  • Train new colleagues and junior staff in manufacturing processes, equipment operation, safety procedures, and company standards.
  • Assist with technical transfer activities for new products and manufacturing processes.
Desired Qualifications
  • A Bachelor's degree in Chemical Engineering, Chemistry, Biology, or a related discipline.
  • Experience supporting the startup and operation of a biopharmaceutical manufacturing process.
  • Experience authoring or editing standard operating procedures.
  • Experience with electronic records and process control software such as DeltaV, Unicorn, Ignition, or similar systems.

1) What does this company do? Kyowa Kirin develops specialty pharmaceutical drugs with a focus on nephrology, oncology, and immunology, built on a foundation of fermentation technology and antibody science. 2) How does this company's product(s) work? It uses fermentation-derived biology and antibody-based approaches to create therapies that target kidney disease, cancer, and immune-related conditions, delivered as approved medicines after research, development, and clinical testing. 3) How is this company different from its competitors? It blends deep fermentation and microbiology expertise with antibody technology from its history, plus a global specialty-drug focus, resulting from a merger of Kyowa Hakko Kogyo and Kirin Pharma that combined fermentation know-how with pharmaceutical resources. 4) What is this company's goal? To develop and commercialize innovative treatments that address unmet medical needs in nephrology, oncology, and immunology on a global scale.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Tokyo, Japan

Founded

1885

Get referred to Kyowa Kirin

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • FDA selected Sanford for PreCheck in June 2026, accelerating biologics launch timelines.
  • H1 FY2026 revenue rose 14% and core operating profit jumped 80%.
  • KOMZIFTI ziftomenib launched in 2025, adding an oncology revenue stream with future expansion.

What critics are saying

  • Rocatinlimab trials ended March 2026 after safety concerns, erasing a major growth option.
  • Sun Pharmaceutical sued Kyowa Kirin in November 2025 over ANDA patent rights.
  • Crysvita concentration remains dangerous; one product drove ¥118.8 billion, about 45% of H1 revenue.

What makes Kyowa Kirin unique

  • Crysvita dominates rare-disease endocrinology, with 2026 sales up 19% globally.
  • Sanford, North Carolina becomes its first U.S. manufacturing hub, operationally targeted for 2027.
  • Kyowa Kirin controls antibody, cell, and gene-therapy platforms across rare-disease franchises.

Help us improve and share your feedback! Did you find this helpful?

Benefits

401(k) Company Match

Paid Vacation

Paid Sick Leave

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Unlimited Paid Time Off

Hybrid Work Options

Pet Insurance

Tuition Assistance

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-1%

2 year growth

-2%
IT Business Today
Aug 17th, 2026
Kyowa Kirin modernizes with Cognizant and Benchling R&D with AI and automation.

Kyowa Kirin modernizes with Cognizant and Benchling R&D with AI and automation. Last updated: August 17, 2026 12:53 pm Kyowa Kirin has chosen Cognizant and Benchling to support the rollout of Benchling's cloud-based R&D platform at its Tokyo Research Park and Fuji Research Park. The platform brings experimental planning, data collection, AI tools, and workflow automation into one place. Researchers can connect experimental equipment directly to Benchling, allowing data to be captured as structured and searchable records instead of being entered manually. That matters as Kyowa Kirin's research work becomes more complex and its pipeline expands. The company expects the platform to help speed up activities ranging from identifying drug targets to selecting new drug candidates. Researchers will also be able to search past experiments, generate reports, examine relationships between studies, and support molecular design using the platform's analytical and AI capabilities. Cognizant will handle the implementation using Benchling, including platform setup, data migration, deployment, and the ongoing upkeep too. This partnership shows where pharma research and development is headed, more or less, these days. More of the work around data handling and routine processes is being moved into connected digital systems, while AI is being brought closer to the research itself rather than treated as a separate tool. ITBT Staffwriter is an in-house contributor at IT Business Today, responsible for delivering timely News and QuickBytes. The author covers the latest developments across IT, tech, and enterprise solutions to keep readers informed with concise and impactful updates. August 17, 2026

Benzinga
Dec 15th, 2025
Link Cell Therapies raises $92M to advance CAR-T cancer treatments for solid and liquid tumors

Link Cell Therapies has emerged from stealth with $60 million in Series A funding led by Johnson & Johnson Innovation – JJDC, bringing total capital raised to $92 million. The South San Francisco–based oncology company is developing CAR-T therapies for solid and liquid tumours using proprietary logic-gating technology. The platform enables safe targeting of multiple antigens co-expressed on cancer cells whilst sparing healthy tissue. Co-founded by Dr Robbie Majzner and Dr Crystal Mackall at Stanford University in 2022, Link's lead programme, LNK001 for renal cell carcinoma, is on track for an IND application and Phase I trial in 2026. The Series A round included participation from founding investors Samsara BioCapital and Sheatree Capital, alongside new backers Bristol Myers Squibb, Kyowa Kirin and Wing Venture Capital.

FinSMEs
Mar 4th, 2025
Garuda Therapeutics Closes $50M Series A-1 Financing

Garuda Therapeutics, a Cambridge, MA-based hematopoietic stem cell (HSC) therapies company, raised $50M in Series A-1 funding

Cimeio Therapeutics
Dec 10th, 2024
Cimeio Therapeutics Announces Partnership with Kyowa Kirin to Develop Novel Cell Therapies

The partnership combines Cimeio's proprietary Shielded Cell and Immunotherapy (SCIP) platform with Kyowa Kirin's expertise in cellular therapies and underscores both companies' commitment to using emerging cell and gene therapy technologies to develop new ways to treat patients.

Business North Carolina
Nov 27th, 2024
Op/ed: Biotech's role in North Carolina's job-creation success

Kyowa Kirin, a Japanese global specialty pharmaceutical company, plans to invest more than $200 million in Sanford to build its first pharmaceutical manufacturing complex in North America, adding more than 100 new jobs.